The strength of binding between sgRNA and target RNA would also need to be considered, since the ASO modified with locked nucleic acids that was designed to target the MALAT1 RNA at the same site as sgRM3 has been shown to effectively reduce the MALAT1 level in myeloma cells [20]. The gene discussed is MALAT1; the disease is plasma cell myeloma.